Oldham Rk

897 total citations
37 papers, 596 citations indexed

About

Oldham Rk is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Biotechnology. According to data from OpenAlex, Oldham Rk has authored 37 papers receiving a total of 596 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Biotechnology. Recurrent topics in Oldham Rk's work include Cancer Research and Treatments (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Immune Cell Function and Interaction (3 papers). Oldham Rk is often cited by papers focused on Cancer Research and Treatments (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Immune Cell Function and Interaction (3 papers). Oldham Rk collaborates with scholars based in United States. Oldham Rk's co-authors include Greco Fa, Richardson Rl, Leslie Burnett, R B Herberman, A E Maluish, West Wh, Thelma M. Watson, Richard D. Leavitt, Robert Birch and Chantal Moratz and has published in prestigious journals such as Seminars in Oncology, PubMed and Munich Personal RePEc Archive (Ludwig Maximilian University of Munich).

In The Last Decade

Oldham Rk

34 papers receiving 507 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Oldham Rk United States 14 264 157 119 102 89 37 596
C.R. Franks United Kingdom 17 302 1.1× 293 1.9× 63 0.5× 88 0.9× 110 1.2× 51 672
Liana De Vecchis Italy 13 543 2.1× 232 1.5× 92 0.8× 73 0.7× 188 2.1× 32 842
Glauce Aparecida Pinto Brazil 12 313 1.2× 110 0.7× 67 0.6× 70 0.7× 132 1.5× 40 635
C. Gropp Germany 16 395 1.5× 61 0.4× 242 2.0× 189 1.9× 288 3.2× 62 806
C.R. Franks France 15 341 1.3× 251 1.6× 29 0.2× 142 1.4× 120 1.3× 34 610
Małgorzata Fuksiewicz Poland 14 321 1.2× 178 1.1× 88 0.7× 70 0.7× 170 1.9× 42 620
Marcella Falchetti Italy 16 274 1.0× 97 0.6× 67 0.6× 126 1.2× 225 2.5× 19 803
I McDicken United Kingdom 14 116 0.4× 58 0.4× 59 0.5× 46 0.5× 131 1.5× 45 500
Shumpei Matsuura Japan 11 154 0.6× 72 0.5× 43 0.4× 119 1.2× 113 1.3× 19 490
H. Parmar United Kingdom 11 92 0.3× 66 0.4× 107 0.9× 177 1.7× 88 1.0× 18 521

Countries citing papers authored by Oldham Rk

Since Specialization
Citations

This map shows the geographic impact of Oldham Rk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oldham Rk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oldham Rk more than expected).

Fields of papers citing papers by Oldham Rk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oldham Rk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oldham Rk. The network helps show where Oldham Rk may publish in the future.

Co-authorship network of co-authors of Oldham Rk

This figure shows the co-authorship network connecting the top 25 collaborators of Oldham Rk. A scholar is included among the top collaborators of Oldham Rk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oldham Rk. Oldham Rk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rk, Oldham. (1991). Cancer research: a public trust.. PubMed. 3(3). 122–3.
2.
Rk, Oldham. (1991). Custom-tailored drug immunoconjugates in cancer therapy.. PubMed. 3(3). 148–62. 7 indexed citations
3.
Rk, Oldham, et al.. (1991). Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a National Biotherapy Study Group Trial.. PubMed. 3(2). 68–73. 13 indexed citations
4.
Wh, West, et al.. (1989). Multiple cycles of constant infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal carcinoma.. PubMed. 1(5). 268–74. 9 indexed citations
5.
Rk, Oldham, et al.. (1989). Chemosensitivity testing in a tumor acquisition, propagation, and preservation program.. PubMed. 1(5). 256–60. 4 indexed citations
6.
Rk, Oldham. (1987). Monoclonal antibodies: does sufficient selectivity to cancer cells exist for therapeutic application?. PubMed. 6(3). 227–34. 5 indexed citations
7.
Rk, Oldham, et al.. (1986). Phase I trials of biological response modifiers.. PubMed. 12(1-3). 31–9. 3 indexed citations
8.
Rk, Oldham. (1985). Interferon: a model for future biologicals.. PubMed. 6. 127–43. 6 indexed citations
9.
Maluish, A E, et al.. (1984). A trial of autologous plasma perfusion over protein A in patients with breast cancer.. PubMed. 3(3). 352–8. 10 indexed citations
10.
Watson, Thelma M., et al.. (1984). A preliminary Phase I trial of partially purified interferon-gamma in patients with cancer.. PubMed. 3(6). 599–607. 19 indexed citations
11.
Rk, Oldham, et al.. (1983). Interferon as a biological response modifying agent in clinical trials.. PubMed. 2(5). 401–8. 15 indexed citations
12.
Rk, Oldham, et al.. (1983). Immunotherapy: the old and the new.. PubMed. 2(1). 1–37. 32 indexed citations
13.
Rk, Oldham. (1983). Biologicals: new horizons in pharmaceutical development.. PubMed. 2(3). 199–206. 6 indexed citations
14.
Leavitt, Richard D., et al.. (1983). Effects of recombinant interferon-alpha on immune function in cancer patients.. PubMed. 2(5). 470–81. 11 indexed citations
15.
Rk, Oldham. (1982). Biological Response Modifiers Programme and cancer chemotherapy.. PubMed. 4(3). 173–88. 3 indexed citations
16.
Rl, Richardson, et al.. (1978). Tumor products and potential markers in small cell lung cancer.. Seminars in Oncology. 5(3). 253–62. 41 indexed citations
17.
Fa, Greco, et al.. (1978). Small cell lung cancer: progress and perspectives.. PubMed. 5(3). 323–35. 81 indexed citations
18.
Wj, Catalona, et al.. (1975). Specificity of in vitro cellular cytotoxicity against transitional cell carcinoma cell line T-24.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 26. 122–124. 4 indexed citations
19.
Rk, Oldham, et al.. (1974). Possible role of lymphocyte cytotoxicity in bone-marrow grafting.. PubMed. 6(4). 417–9. 2 indexed citations
20.
Rk, Oldham. (1970). Terminal cancer: a patient oriented approach.. PubMed. 63(3). 206–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026